DOCSLIB.ORG

First Draft of the National Chemicals Inventory (Rev. As of March 15 2017) No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
First Draft of the National Chemicals Inventory (Rev. As of March 15 2017) No First draft of the National Chemicals Inventory (rev. as of March 15 2017) No. CAS Chemical Name (proposal) 1 50-00-0 Formaldehyde 2 50-01-1 Guanidine hydrochloride 3 50-02-2 9-Fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 4 50-03-3 Hydrocortisone acetate 5 50-14-6 Ergocalciferol 6 50-21-5 2-Hydroxypropanoic acid 7 50-23-7 Cortisol 8 50-24-8 Prednisolone 9 50-27-1 Estriol 10 50-32-8 Benzo[a]pyrene 11 50-37-3 Lysergide 12 50-70-4 D-Glucitol 13 50-78-2 Aspirin 14 50-81-7 L-ascorbic acid 15 50-99-7 D-Glucose 16 51-03-6 5-Propan-1-yl-6-(2,5,8-trioxadodecan-1-yl)-1,3-benzodioxole 17 51-21-8 Fluorouracil 18 51-45-6 2-imidazol-4-ylethylamine 19 52-01-7 7alpha-(Acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone 20 52-28-8 Codeine phosphate 21 52-49-3 Trihexyphenidyl hydrochloride 22 52-51-7 2-Bromo-2-nitropropane-1,3-diol 23 52-76-6 Lynestrenol 24 52-89-1 Cysteine hydrochloride 25 52-90-4 L-cysteine 26 53-36-1 Methylprednisolone 21-acetate 27 53-86-1 Indometacin 28 54-05-7 Chloroquine 29 54-21-7 Sodium salicylate 30 54-31-9 Furosemide 31 54-64-8 Sodium ethanide[2-(sulfide-kappaS)benzoato-kappaO]mercurate(1-) 32 54-86-4 Sodium nicotinate 33 55-63-0 Nitroglycerin 34 55-86-7 Bis(2-chloroethyl)(methyl)ammonium chloride 35 56-04-2 Methylthiouracil 36 56-12-2 4-aminobutyric acid 37 56-17-7 2,2'-dithiodi(ethylammonium) dichloride 38 56-23-5 Tetrachloromethane 39 56-40-6 Glycine 40 56-41-7 L-alanine 41 56-45-1 L-Serine 42 56-53-1 (E)-4,4'-Hex-3-ene-3,4-diyldiphenol 43 56-72-4 Coumaphos 44 56-75-7 Chloramphenicol 45 56-81-5 Glycerol 46 56-84-8 L-Aspartic acid 47 56-86-0 Glutamic acid 48 56-89-3 Cystine 49 56-92-8 2-imidazol-4-ylethylamine dihydrochloride 50 57-03-4 1,2,3-Propanetriol, 1-(dihydrogen phosphate) 51 57-09-0 Cetrimonium bromide 52 57-10-3 Palmitic acid 53 57-11-4 Stearic acid 54 57-13-6 Urea 55 57-15-8 Chlorbutanol 56 57-24-9 Strychnine 57 57-48-7 D-Fructose 1/93 58 57-50-1 Sucrose 59 57-55-6 Propane-1,2-diol 60 57-63-6 Ethynyl estradiol 61 58-08-2 1,3,7-Trimethyl-1H-purine-2,6(3H,7H)-dione 62 58-22-0 Testosterone 63 58-27-5 Menadione 64 58-55-9 1,3-Dimethyl-1H-purine-2,6(3H,9H)-dione 65 58-56-0 3-Hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridin-1-ium chloride 66 58-61-7 Adenosine 67 58-71-9 Cefalotin sodium 68 58-73-1 Diphenhydramine 69 58-85-5 Biotin 70 58-93-5 Hydrochlorothiazide 71 58-95-7 alpha-tocopheryl acetate 72 59-02-9 alpha-tocopherol 73 59-05-2 Methotrexate 74 59-23-4 Galactose 75 59-26-7 Nikethamide 76 59-30-3 Folic acid 77 59-43-8 Thiamine 78 59-47-2 Mephenesin 79 59-50-7 4-Chloro-3-methylphenol 80 59-51-8 DL-Methionine 81 59-67-6 Nicotinic acid 82 59-88-1 Phenylhydrazinium chloride 83 59-92-7 (S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid 84 60-00-4 Ethylenediaminetetraacetic acid 85 60-10-6 1,5-diphenyl-3-thiocarbazone 86 60-11-7 4-dimethylaminoazobenzene 87 60-12-8 .beta.-Phenylethylalcohol 88 60-18-4 Tyrosine 89 60-24-2 Ethanol, 2-mercapto- 90 60-29-7 Ethane, 1,1'-oxybis 91 60-32-2 Aminocaproic acid 92 60-33-3 Linoleic acid 93 60-35-5 Acetamide 94 60-51-5 Dimethoate 95 61-68-7 Mefenamic acid 96 61-73-4 3,7-Bis(N,N-dimethylamino)phenothiazin-5-ium chloride 97 61-76-7 Phenylephrine hydrochloride 98 61-90-5 L-leucine 99 62-46-4 5-(1,2-dithiolan-3-yl)valeric acid 100 62-49-7 Choline 101 62-53-3 Aniline 102 62-55-5 Thioacetamide 103 62-56-6 Thiourea 104 62-73-7 Dichlorvos 105 62-75-9 Dimethylnitrosoamine 106 62-76-0 Disodium oxalate 107 63-25-2 Carbaryl 108 63-42-3 Lactose 109 63-45-6 Primaquine bis(phosphate) 110 63-68-3 L-Methionine 111 63-74-1 4-Aminobenzenesulfonamide 112 63-91-2 L-Phenylalanine 113 64-02-8 Tetrasodium 2,2',2'',2'''-(ethylenedinitrilo)tetraacetate 114 64-17-5 Ethanol 115 64-18-6 Formic acid 116 64-19-7 Acetic acid 117 64-67-5 Diethyl sulfate 2/93 118 64-86-8 (S)-N-(1,2,3,10-Tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide 119 65-23-6 Pyridoxine 120 65-71-4 5-methyluracil 121 65-85-0 Benzoic acid 122 65-86-1 Orotic acid 123 66-71-7 1,10-phenanthroline 124 66-84-2 Glucosamine hydrochloride 3-[(4-Amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methylthiazol-3-ium 125 67-03-8 chloride monohydrochloride N,N'-[dithiobis[2-(2-hydroxyethyl)-1-methylvinylene]]bis[N-[(4-amino-2-methyl-5- 126 67-16-3 pyrimidinyl)methyl]formamide 127 67-43-6 N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid) 128 67-48-1 2-Hydroxy-N,N,N-trimethylethanaminium chloride 129 67-52-7 Barbituric acid 130 67-56-1 Methanol 131 67-63-0 Propan-2-ol 132 67-64-1 Acetone 133 67-66-3 Chloroform 134 67-68-5 Dimethyl sulfoxide 135 67-71-0 Dimethyl sulphone 136 67-97-0 Colecalciferol 137 68-04-2 Trisodium citrate 138 68-11-1 Acetic acid, mercapto- 139 68-12-2 N,N-Dimethylformamide 140 68-19-9 Cyanocobalamin 141 68-35-9 Sulfadiazine 142 68-59-7 Prednisone Sodium [(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4- 143 68-89-3 yl)methylamino]methanesulphonate 144 69-09-0 Chlorpromazine hydrochloride Sodium [2S-[2alpha,5alpha,6beta(S*)]]-6-(aminophenylacetamido)-3,3-dimethyl-7-oxo-4- 145 69-52-3 thia-1-azabicyclo[3.2.
Load more

Recommended publications
  • Complementary and Alternative Treatments for Alopecia: a Comprehensive Review
    Review Article Skin Appendage Disord 2019;5:72–89 Received: April 22, 2018 DOI: 10.1159/000492035 Accepted: July 10, 2018 Published online: August 21, 2018 Complementary and Alternative Treatments for Alopecia: A Comprehensive Review Anna-Marie Hosking Margit Juhasz Natasha Atanaskova Mesinkovska Department of Dermatology, University of California, Irvine, Irvine, CA, USA Keywords Introduction Alopecia · Complementary and alternative medicine · Efficacy According to the National Center for Complementary and Integrative Health (NCCIH), a branch of the Nation- al Institutes of Health (NIH; Bethesda, MD, USA), more Abstract than 30% of adults and 12% of children utilize treatments The treatment of alopecia is limited by a lack of therapies developed “outside of mainstream Western, or conven- that induce and sustain disease remission. Given the nega- tional, medicine,” with a total USD 30.2 billion out-of- tive psychosocial impact of hair loss, patients that do not pocket dollars spent annually [1]. In the treatment of alo- see significant hair restoration with conventional therapies pecia, there is an unmet need for therapies providing sat- often turn to complementary and alternative medicine isfying, long-term results. Patients often turn to (CAM). Although there are a variety of CAM treatment op- complementary and alternative medicine (CAM) in an tions on the market for alopecia, only a few are backed by attempt to find safe, natural, and efficacious therapies to multiple randomized controlled trials. Further, these mo- restore hair. Although CAMs boast hair-growing poten- dalities are not regulated by the Food and Drug Administra- tial, patients may be disappointed with results as there is tion and there is a lack of standardization of bioactive in- a lack of standardization of bioactive ingredients and lim- gredients in over-the-counter vitamins, herbs, and supple- ited scientific evidence.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IB20 14/060675 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 12 April 2014 (12.04.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: zw. 1103/DEL/2013 12 April 2013 (12.04.2013) IN (84) Designated States (unless otherwise indicated, for every (71) Applicant: VYOME BIOSCIENCES PVT. LTD. kind of regional protection available): ARIPO (BW, GH, [IN/IN]; 459 F.I.E, First Floor, Patparganj Industrial Area, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, New Delhi 110092 (IN).
    [Show full text]
  • Brochure-Product-Range.Pdf
    PRODUCT RANGE 2015 edition ANSI Standard 60 NSF® CERTIFIED HALAL M ISLAMIC FOOD AND NUTRITION ® COUNCIL OF AMERICA Rue Joseph Wauters, 144 ISO 9001:2008 (Quality) / OHSAS 18001:2007 (Health/ B-4480 Engis Safety) / ISO 14001:2004 (Environment) / ISO 22000:2005 www.globulebleu.com (Food Safety) / FSSC 22000:2013 (Food Safety). Tel. +32 (0) 4 273 93 58 Our food grade phosphates are allergen free, GMO free, Fax. +32 (0) 4 275 68 36 BSE/TSE free. www.prayon.com mail. [email protected] Design by www.prayon.com PRODUCT RANGE | 11 TABLE OF CONTENTS HORTICULTURE APPLICATIONS HORTIPRAY® RANGE FOR HORTICULTURE* FOOD AND INDUSTRIAL APPLICATIONS PRODUCT NAME Bulk density P O pH N-NH Made 2 5 4 MONOAMMONIUM PHOSPHATE - NH4H2PO4 in 3 3 % 1% % Sodium orthophosphates ................................................................................... 03 g/cm lbs/ft indicative indicative indicative Water-soluble fertilisers. Sodium pyrophosphates .................................................................................... 04 HORTIPRAY® MAP Horticultural Grade 0.9 56 61 4.5 12 Sodium tripolyphosphates ................................................................................. 05 HORTIPRAY® MAP 12.60 Horticultural Grade 0.9 56 60 5 12.1 Water-soluble fertilisers; Sodium polyphosphates ..................................................................................... 06 HORTIPRAY® MAP anticalc Horticultural Grade 0.9 56 61 4.5 12 preventive action against clogging. Potassium orthophosphates .............................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0124724 A1 Burton Et Al
    US 2005O124724A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0124724 A1 Burton et al. (43) Pub. Date: Jun. 9, 2005 (54) POLYMER COMPOSITIONS WITH (21) Appl. No.: 10/728,439 BIOACTIVE AGENT, MEDICAL ARTICLES, AND METHODS (22) Filed: Dec. 5, 2003 (75) Inventors: Scott A. Burton, Woodbury, MN (US); Publication Classification Patrick D. Hyde, Burnsville, MN (US); Prabhakara S. Rao, Maplewood, MN (51) Int. Cl." ....................................................... C08K 3/00 (US); Caroline M. Ylitalo, Stillwater, (52) U.S. Cl. .............................................................. 523/122 MN (US) (57) ABSTRACT Correspondence Address: A polymer composition that includes a hydrophilic polymer, 3M INNOVATIVE PROPERTIES COMPANY an optional Secondary organic polymer, and a bioactive PO BOX 33427 agent distributed therein, wherein the bioactive agent is ST. PAUL, MN 55133-3427 (US) Selected from the group consisting of a Silver compound, a copper compound, a Zinc compound, and combinations (73) Assignee: 3M Innovative Properties Company thereof. US 2005/O124724 A1 Jun. 9, 2005 POLYMER COMPOSITIONS WITH BOACTIVE comprising absorbent hydrophilic microparticles, a metal AGENT, MEDICAL ARTICLES, AND METHODS compound Selected from the group consisting of a Silver compound, a copper compound, a Zinc compound, and BACKGROUND combinations thereof, wherein the Silver compound has a 0001 Polymer compositions that include bioactive Solubility of at least 0.1 gram per liter in water; and a agents (e.g., antimicrobial agents) are used for a variety of hydroxide Source that converts the metal compound to the applications, particularly medical applications Such as corresponding metal oxide. The components are combined wound dressings and wound packing materials. Conven in a manner to incorporate the metal oxide within the tional antimicrobial agents include ionizable Silver com microparticles.
    [Show full text]
  • Ionic Liquid + Biomolecule
    Sónia Isabel Pereira Branco Licenciatura em Ciências da Engenharia Química e Bioquímica Aqueous Biphasic System based on Cholinium Ionic Liquids: Extraction of Biologically Active Phenolic Acids Dissertação para obtenção do Grau de Mestre em Engenharia Química e Bioquímica Orientador: Doutora Isabel Maria Delgado Jana Marrucho Ferreira, Investigadora Coordenadora, Laboratório de Termodinâmica Molecular, ITQB-UNL Presidente: Doutora Susana Filipe Barreiros Arguente: Doutor Alexandre Babo de Almeida Paiva Vogal: Doutora Isabel Maria Delgado Jana Marrucho Ferreira Setembro 2014 II UNIVERSIDADE NOVA DE LISBOA Faculdade de Ciências e Tecnologia Departamento de Química Aqueous Biphasic System based on Cholinium Ionic Liquids: Extraction of Biologically Active Phenolic Acids Sónia Isabel Pereira Branco Dissertação apresentada na Faculdade de Ciências e Tecnologia da Universidade Nova de Lisboa para obtenção do grau Mestre em Engenharia Química e Bioquímica Orientadores: Doutora Isabel Maria Delgado Jana Marrucho Ferreira 2014 III IV Aqueous Biphasic Systems based on Cholinium Ionic Liquids: Extraction of Biologically Active Phenolic Acids COPYRIGHT Sónia Isabel Pereira Branco Faculdade de Ciências e Tecnologia Universidade Nova de Lisboa A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. V VI Agradecimentos Durante a realização desta tese, contei com o apoio de várias pessoas sem as quais não teria concluído esta etapa.
    [Show full text]
  • Drug Consumption in 2017 - 2020
    Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Beneficial and Deleterious Effects of Female Sex Hormones, Oral
    International Journal of Molecular Sciences Review Beneficial and Deleterious Effects of Female Sex Hormones, Oral Contraceptives, and Phytoestrogens by Immunomodulation on the Liver Luis E. Soria-Jasso 1, Raquel Cariño-Cortés 1,Víctor Manuel Muñoz-Pérez 1, Elizabeth Pérez-Hernández 2, Nury Pérez-Hernández 3 and Eduardo Fernández-Martínez 1,* 1 Laboratory of Medicinal Chemistry and Pharmacology, Centro de Investigación en Biología de la Reproducción, Área Académica de Medicina, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado de Hidalgo. Calle Dr. Eliseo Ramírez Ulloa no. 400, Col. Doctores, Pachuca Hidalgo 42090, Mexico; [email protected] (L.E.S.-J.); [email protected] (R.C.-C.); [email protected] (V.M.M.-P.) 2 Hospital de Ortopedia “Dr. Victorio de la Fuente Narváez”, IMSS, Mexico 07760, Mexico; [email protected] 3 Programa Institucional de Biomedicina Molecular, Escuela Nacional de Medicina y Homeopatía, Instituto Politécnico Nacional, Mexico 07320, Mexico; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +52-771-717-2000 Received: 14 August 2019; Accepted: 20 September 2019; Published: 22 September 2019 Abstract: The liver is considered the laboratory of the human body because of its many metabolic processes. It accomplishes diverse activities as a mixed gland and is in continuous cross-talk with the endocrine system. Not only do hormones from the gastrointestinal tract that participate in digestion regulate the liver functions, but the sex hormones also exert a strong influence on this sexually dimorphic organ, via their receptors expressed in liver, in both health and disease. Besides, the liver modifies the actions of sex hormones through their metabolism and transport proteins.
    [Show full text]
  • Comparative Study of Oestrogenic Properties of Eight Phytoestrogens in MCF7 Human Breast Cancer Cells A
    Journal of Steroid Biochemistry & Molecular Biology 94 (2005) 431–443 Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells A. Matsumura, A. Ghosh, G.S. Pope, P.D. Darbre ∗ Division of Cell and Molecular Biology, School of Animal and Microbial Sciences, The University of Reading, P.O. Box 228, Whiteknights, Reading RG6 6AJ, UK Received 26 August 2004; received in revised form 3 November 2004; accepted 17 December 2004 Abstract Previous studies have compared the oestrogenic properties of phytoestrogens in a wide variety of disparate assays. Since not all phytoe- strogens have been tested in each assay, this makes inter-study comparisons and ranking oestrogenic potency difficult. In this report, we have compared the oestrogen agonist and antagonist activity of eight phytoestrogens (genistein, daidzein, equol, miroestrol, deoxymiroestrol, 8-prenylnaringenin, coumestrol and resveratrol) in a range of assays all based within the same receptor and cellular context of the MCF7 human breast cancer cell line. The relative binding of each phytoestrogen to oestrogen receptor (ER) of MCF7 cytosol was calculated from 3 the molar excess needed for 50% inhibition of [ H]oestradiol binding (IC50), and was in the order coumestrol (35×)/8-prenylnaringenin (45×)/deoxymiroestrol (50×) > miroestrol (260×) > genistein (1000×) > equol (4000×) > daidzein (not achieved: 40% inhibition at 104-fold molar excess) > resveratrol (not achieved: 10% inhibition at 105-fold molar excess). For cell-based assays, the rank order of potency (estimated in terms of the concentration needed to achieve a response equivalent to 50% of that found with 17␤-oestradiol (IC50)) remained very similar for all the assays whether measuring ligand ability to induce a stably transfected oestrogen-responsive ERE-CAT reporter gene, cell growth in terms of proliferation rate after 7 days or cell growth in terms of saturation density after 14 days.
    [Show full text]